Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Momelotinib dihydrochloride by GSK for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Momelotinib dihydrochloride is under clinical development by GSK and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Momelotinib dihydrochloride by GSK for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Momelotinib dihydrochloride is under clinical development by GSK and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Momelotinib dihydrochloride by GSK for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval
Momelotinib dihydrochloride is under clinical development by GSK and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According...